PL373946A1 - Phenoxy piperidines for treating diseases such as schizophrenia and depression - Google Patents
Phenoxy piperidines for treating diseases such as schizophrenia and depressionInfo
- Publication number
- PL373946A1 PL373946A1 PL02373946A PL37394602A PL373946A1 PL 373946 A1 PL373946 A1 PL 373946A1 PL 02373946 A PL02373946 A PL 02373946A PL 37394602 A PL37394602 A PL 37394602A PL 373946 A1 PL373946 A1 PL 373946A1
- Authority
- PL
- Poland
- Prior art keywords
- schizophrenia
- depression
- treating diseases
- piperidines
- phenoxy
- Prior art date
Links
- BRUWSFUBFQYNPG-UHFFFAOYSA-N 1-phenoxypiperidine Chemical class C1CCCCN1OC1=CC=CC=C1 BRUWSFUBFQYNPG-UHFFFAOYSA-N 0.000 title 1
- 208000020401 Depressive disease Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10201550A DE10201550A1 (de) | 2002-01-17 | 2002-01-17 | Phenoxy-Piperidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL373946A1 true PL373946A1 (en) | 2005-09-19 |
Family
ID=7712334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL02373946A PL373946A1 (en) | 2002-01-17 | 2002-12-17 | Phenoxy piperidines for treating diseases such as schizophrenia and depression |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20050131021A1 (https=) |
| EP (1) | EP1465868A1 (https=) |
| JP (1) | JP4727925B2 (https=) |
| CN (1) | CN1615297A (https=) |
| AU (1) | AU2002358735B9 (https=) |
| CA (1) | CA2473409C (https=) |
| DE (1) | DE10201550A1 (https=) |
| HU (1) | HUP0500497A2 (https=) |
| PL (1) | PL373946A1 (https=) |
| WO (1) | WO2003059882A1 (https=) |
| ZA (1) | ZA200406504B (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20050861A1 (es) * | 2003-12-03 | 2005-12-10 | Glaxo Group Ltd | Derivados de sales ciclicas de amonio cuaternario como antagonistas del receptor muscarinico de acetilcolina |
| EP1928437A2 (en) | 2005-08-26 | 2008-06-11 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| US8787440B2 (en) * | 2008-07-25 | 2014-07-22 | Qualcomm Incorporated | Determination of receive data values |
| RU2014121984A (ru) | 2011-10-31 | 2015-12-10 | Ксенон Фармасьютикалз Инк. | Бензолсульфонамидные соединения и их применение в качестве терапевтических средств |
| JP6014155B2 (ja) | 2011-10-31 | 2016-10-25 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用 |
| CN104718188B (zh) | 2012-05-22 | 2018-08-21 | 基因泰克公司 | N-取代的苯甲酰胺类及其在治疗疼痛中的用途 |
| KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
| RU2015143906A (ru) | 2013-03-14 | 2017-04-18 | Дженентек, Инк. | Замещенные триазолопиридины и способы их применения |
| BR112015023397A2 (pt) | 2013-03-15 | 2017-07-18 | Genentech Inc | benzoxazois substituídos e métodos de uso dos mesmos |
| WO2015078374A1 (en) | 2013-11-27 | 2015-06-04 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| JP2017525677A (ja) | 2014-07-07 | 2017-09-07 | ジェネンテック， インコーポレイテッド | 治療用化合物及びその使用方法 |
| HK1252567A1 (zh) | 2015-05-22 | 2019-05-31 | 基因泰克公司 | 被取代的苯甲酰胺和其使用方法 |
| JP2018526371A (ja) | 2015-08-27 | 2018-09-13 | ジェネンテック， インコーポレイテッド | 治療化合物及びその使用方法 |
| CA2999769A1 (en) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| PE20190980A1 (es) | 2016-10-17 | 2019-07-09 | Genentech Inc | Compuestos terapeuticos y metodos para utilizarlos |
| WO2018112842A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018112840A1 (en) | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| WO2018112843A1 (en) * | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor |
| JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック， インコーポレイテッド | ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体 |
| AR114263A1 (es) | 2018-02-26 | 2020-08-12 | Genentech Inc | Compuestos terapéuticos y métodos para utilizarlos |
| US10947251B2 (en) | 2018-03-30 | 2021-03-16 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
| TW202003490A (zh) | 2018-05-22 | 2020-01-16 | 瑞士商赫孚孟拉羅股份公司 | 治療性化合物及其使用方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2776293A (en) * | 1950-08-09 | 1957-01-01 | Nopco Chem Co | Improved hydrogenation process |
| US4216218A (en) * | 1979-02-23 | 1980-08-05 | American Hoechst Corporation | Antidepressant and analgesic 4-aryloxy- and 4-arylthio-3-phenylpiperidines |
| EG18188A (en) * | 1986-05-01 | 1992-09-30 | Pfizer Ltd | Process for preparation anti-arhythmia agents |
| US5093341A (en) * | 1987-12-17 | 1992-03-03 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine derivatives useful as antithrombolytic agents |
| US5169855A (en) * | 1990-03-28 | 1992-12-08 | Du Pont Merck Pharmaceutical Company | Piperidine ether derivatives as psychotropic drugs or plant fungicides |
| US5202346A (en) * | 1992-02-25 | 1993-04-13 | American Home Products Corporation | Piperidinyl and piperazinyl derivatives |
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| ZA9610741B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| IL128524A0 (en) * | 1996-08-15 | 2000-01-31 | Schering Corp | Ether muscarinic antagonists |
| GB9725541D0 (en) * | 1997-12-02 | 1998-02-04 | Pharmacia & Upjohn Spa | Amino-benzothiazole derivatives |
| DE10000739A1 (de) * | 2000-01-11 | 2001-07-12 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
| JP2002363159A (ja) * | 2001-04-05 | 2002-12-18 | Sankyo Co Ltd | ベンズアミジン誘導体 |
| AU2003248571A1 (en) * | 2002-05-24 | 2003-12-12 | Neurion Pharmaceuticals, Inc. | Methods of determining precise herg interactions and altering compounds based on said interactions |
-
2002
- 2002-01-17 DE DE10201550A patent/DE10201550A1/de not_active Withdrawn
- 2002-12-17 CA CA2473409A patent/CA2473409C/en not_active Expired - Fee Related
- 2002-12-17 JP JP2003559986A patent/JP4727925B2/ja not_active Expired - Fee Related
- 2002-12-17 WO PCT/EP2002/014389 patent/WO2003059882A1/de not_active Ceased
- 2002-12-17 CN CNA028272544A patent/CN1615297A/zh active Pending
- 2002-12-17 US US10/501,763 patent/US20050131021A1/en not_active Abandoned
- 2002-12-17 HU HU0500497A patent/HUP0500497A2/hu unknown
- 2002-12-17 EP EP02793045A patent/EP1465868A1/de not_active Withdrawn
- 2002-12-17 PL PL02373946A patent/PL373946A1/xx unknown
- 2002-12-17 AU AU2002358735A patent/AU2002358735B9/en not_active Ceased
-
2004
- 2004-08-16 ZA ZA200406504A patent/ZA200406504B/en unknown
-
2009
- 2009-02-26 US US12/393,480 patent/US20090247584A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002358735A1 (en) | 2003-07-30 |
| AU2002358735B2 (en) | 2009-03-12 |
| JP2005514457A (ja) | 2005-05-19 |
| JP4727925B2 (ja) | 2011-07-20 |
| AU2002358735B9 (en) | 2009-04-09 |
| US20090247584A1 (en) | 2009-10-01 |
| DE10201550A1 (de) | 2003-07-31 |
| CA2473409C (en) | 2011-09-27 |
| CN1615297A (zh) | 2005-05-11 |
| HUP0500497A2 (hu) | 2005-08-29 |
| CA2473409A1 (en) | 2003-07-24 |
| US20050131021A1 (en) | 2005-06-16 |
| ZA200406504B (en) | 2005-09-15 |
| EP1465868A1 (de) | 2004-10-13 |
| WO2003059882A1 (de) | 2003-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL373946A1 (en) | Phenoxy piperidines for treating diseases such as schizophrenia and depression | |
| IL160933A0 (en) | Methods and compositions for treating ?cap associated diseases | |
| IL208191A0 (en) | Compositions and methods for treating rage-associated disorders | |
| MY143799A (en) | Compositions and methods for treating diabetes | |
| EP1737482A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES | |
| IL172194A0 (en) | Methods and compositions for treating amyloid-related diseases | |
| EP1545578A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASES | |
| AU2003212323A1 (en) | Benzodiazepine-substituted piperidines for utilization in the treatment of cardiovascular diseases | |
| AU2003212850A8 (en) | Methods and compositions for treating cardiovascular disease | |
| GB0303609D0 (en) | Novel therapeutic method and compositions | |
| AU2003232044A8 (en) | Composition and method for dermatological treatment | |
| EP1461047A4 (en) | COMPOSITIONS AND METHODS FOR TREATING ANIMALS | |
| AU2003259202A8 (en) | Compositions and methods for treating and preventing infection | |
| HUP0600855A3 (en) | Androgen pharmaceutical composition for treating depression | |
| IL166062A0 (en) | Compositions and methods for therapeutic treatment | |
| AU2003214920A8 (en) | Methods and compositions for treating hematological disorders | |
| AU2003298708A8 (en) | Gpc99 and gpc99a: methods and compositions for treating cancer | |
| AU2003291730A8 (en) | Methods and compositions for treating neurodegenerative diseases | |
| AU2003275433A8 (en) | Compositions and methods for treating pain | |
| GB0303600D0 (en) | Novel therapeutic method and compositions | |
| AU2003230848A1 (en) | Methods and compositions for treating alzheimer's disease | |
| IL163878A0 (en) | Compositions and methods for treating mdma-inducedtoxicity | |
| AU2002342188A8 (en) | Methods and compositions for treating flavivirus-mediated disease | |
| GB0203528D0 (en) | Process and composition | |
| AU2003295604A8 (en) | Gpc15: methods and compositions for treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |